Corcept Therapeutics Incorporated (CORT)
Corcept Submits Application for Another Cushing's Syndrome Drug
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept Therapeutics: A Most Promising And Compelling Biotech
Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust financials, strong profitability, and near-monopolistic position in a niche market underscore its investment potential despite legal risks and reliance on a single product. The company's innovative pipeline, especially Relacorilant, could significantly expand its market reach and diversify revenue streams, driving strong future growth.
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept Shares Rise More Than 60% in Three Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
3 Reasons Growth Investors Will Love Corcept (CORT)
Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
